DG-1E12 / University of Tours - LARVOL DELTA

The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies. (PubMed, Haematologica) - "In conclusion, 1E12 is a potentially important tool to study the pathophysiology of VITT, and for establishing mouse models. On the other hand, DG-1E12 may help the development of a new drug that specifically neutralizes the pathogenic effect of autoimmune anti-PF4 antibodies, such as those associated with VITT."

Journal • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Novel Coronavirus Disease • Thrombocytopenia • Thrombosis

The Deglycosylated Form of 1E12, a Monoclonal Anti-PF4 IgG, Strongly Inhibits Antibody-Triggered Cellular Activation in Vaccine-Induced Thrombotic Thrombocytopenia, and Is a Potential New Treatment for Vιττ (ASH 2021) - "Our data also demonstrate that DG-1E12 prevents blood cell activation and thrombus formation induced by VITT antibodies, likely due to the competitive effect of its Fab fragment on antibody binding to PF4. DG-1E12 may allow the development of a new drug neutralizing the pathogenic effect of autoimmune anti-PF4 antibodies, such as those associated with VITT."

Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Novel Coronavirus Disease • Thrombocytopenia • Thrombosis